Genmab expands use of IDBS’ ActivityBase Xtended Edition in Hybridoma Discovery

12 Sept 2007
Greg Smith
Analyst / Analytical Chemist

IDBS, an industry leading provider of drug discovery data management solutions, today announced that Genmab BV (Utrecht, The Netherlands) has extended its use of ActivityBase Xtended Edition (ActivityBase XE) within its Hybridoma Discovery department. Genmab initially purchased ActivityBase XE in 2006 to handle the design, capture, storage and retrieval of their plate-based screening data. Following the successful implementation, Genmab has more than doubled the number of ActivityBase XE licenses.

With multiple monoclonal antibody products currently in development or under evaluation to treat cancer, inflammatory conditions and infectious diseases, international biotechnology company Genmab sought a data management solution that had the flexibility to handle the data produced from the functional screening of human monoclonal antibody therapies. ActivityBase XE enables scientists at Genmab to capture, validate and visualize the data from antibody screening in a contextually rich environment.

Links

Tags